Sutro Biopharma (STRO) Tax Provisions (2022 - 2025)

Sutro Biopharma has disclosed Tax Provisions across 4 years of filings, most recently posting -$89000.0 for Q4 2025.

• Tax Provisions for Q4 2025 came in at -$89000.0, down 103.72% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.3 million (down 87.45% YoY), and the FY2025 annual result was -$100000.0, down 104.17% from the prior year.
• Tax Provisions came in at -$89000.0 for Q4 2025 at Sutro Biopharma, down from -$18000.0 in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $15.8 million in Q4 2023 to a low of -$89000.0 in Q4 2025.
• The 4-year median for Tax Provisions is $395000.0 (2023), against an average of $2.6 million.
• Across the five-year window, Tax Provisions sank 84.87% in 2024 and slumped 325.0% in 2025, its largest moves.
• Sutro Biopharma's Tax Provisions stood at $2.5 million in 2022, then surged by 532.28% to $15.8 million in 2023, then tumbled by 84.87% to $2.4 million in 2024, then slumped by 103.72% to -$89000.0 in 2025.
• The last three Tax Provisions figures came in at -$89000.0 (Q4 2025), -$18000.0 (Q2 2025), and $2.4 million (Q4 2024), per Business Quant data.